doi: 10.1007/s13300-019-00686-z 21 MonamiMZannoniSPalaLSilveriiAAndreozziFSestiGet al
[2] Willoughby, D., Hewlings, S., & Kalman, D
In the OASIS-1 study, 13% of participants (people with obesity without diabetes) receiving oral semaglutide 50 mg experienced altered skin sensation events compared to 1% with placebo - these events were generally mild to moderate in severity, occurred during dose escalation to the higher doses and resolved without requiring permanent treatment discontinuation [21]
They are essential infrastructure for data-driven clinical trial execution
Pharmacological approaches to glycemic treatments: standards of care in diabetes 2023
Pharma The rise of GLP-1 receptor agonists, oral obesity drugs, and advanced diabetes treatments is redefining the U.S